Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to …
Post
-
-
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
Akeso has received approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to …
-
FDA grants priority review for Roche’s Tecentriq combo sBLA
Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for …
-
Drug developers eye sport’s biggest stage as World Cup fever builds
As Mexico prepares to take on South Africa in the opening game of the 2026 FIFA World Cup today (11 …
-
XtalPi enters $400m partnership for small molecule therapy for GPCR target
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule …
-
XtalPi enters $400m partnership for small molecule therapy for GPCR target
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule …
-
Beren pockets $300m to take Niemann-Pick disease therapy to market
Beren Therapeutics has secured $300m in combined funding to support the potential commercial launch of its infantile-onset Niemann-Pick disease, type …
-
EMA validates Bayer’s asundexian application for ischaemic stroke
The European Medicines Agency (EMA) has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent …
-
Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public …
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
-
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed …
-
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
Eli Lilly has inked a licensing deal worth up to $1bn with Swedish Alzheimer’s-focused biotech, AlzeCure – marking a continuation …
-
Aditxt and Ignite announce merger plans with strategic partner
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination …
-
MHRA to roll out new AI sandbox for medicines development
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to launch a new AI sandbox to expedite …
-
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long …
